Background: It is unclear whether the prevalence of gallbladder stones (GBS) is higher in patients with chronic kidney disease (CKD). Methods: A total of 398 patients with CKD of each of the 5 disease stages [CKD1: 26; CKD2: 52; CKD3: 58; CKD4: 48; CKD5: 214, of whom 61 were predialysis and 153 were on dialysis (CKD5D)] were included in this study. Those in whom GBS were detected by ultrasonographic examination or who had a history of cholecystectomy owing to GBS were considered GBS patients. Results: In comparison to the GBS prevalence of 5.9% in the control group, that in CKD patients increased with the advancement of the disease stage (CKD1: 7.7%; CKD2: 15.4%; CKD3: 19.0%; CKD4: 20.8%; CKD5 predialysis: 21.3%; CKD5D: 22.9%). The prevalence was significantly greater in CKD5 patients than in the control group. CKD5 is a risk factor for GBS independent of age or sex. However, no significant relationship was found between the prevalence of GBS and the duration of hemodialysis therapy in CKD5D patients. Age was the only factor that was associated with GBS in predialysis CKD patients. Conclusion: The risk of GBS formation was high in predialysis CKD patients. Although the risk disappeared in CKD5D patients, the prevalence of GBS was still significantly higher than in the control population. Factors that promote GBS formation in predialysis CKD patients and/or that inhibit GBS formation in CKD5D patients remain unknown.

Keywords:
Gall bladder stones, Chronic kidney disease, Hemodialysis
1.
Shaffer EA: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006;20:981–996.
2.
Yeh CN, Chen MF, Jan YY: Laparoscopic cholecystectomy for 58 end stage renal disease patients. Surg Endosc 2005;19:915–918.
3.
Sarkio S, Salmela K, Kyllonen L, et al: Complication of gallstone disease in kidney transplantation patients. Nephrol Dial Transplant 2007;22:886–890.
4.
Gladziwa U, Wagner S, Riel J, Sieberth HG: Prevalence of cholelithiasis in haemodialysis patients. Nephrol Dial Transplant 1993;8:1397–1440.
5.
Hojs R: Cholecystolithiasis in patients with end-stage renal disease treated with haemodialysis: a study of prevalence. Am J Nephrol 1995;15:15–17.
6.
Paydas S, Seyrek N, Gorkel Y, Sagliker Y: Prevalence of cholelithiasis in patients with end-stage renal disease. Nephron 1996;72:115–116.
7.
Korzets Z, Golan E, Ben-Chitrii S, et al: Prevalence of cholelithiasis in non-diabetic haemodialysis and continuous ambulatory peritoneal dialysis patients. Nephron 1998;78:44–47.
8.
Dumlu S, Bali M, Yilmaz M, et al: Prevalence of gallstone disease in hemodialysis patients. Nephron 1998;78:347–348.
9.
Altipalmak MR, Pamuk ON, Pamuk GE, et al: Incidence of gallstones in chronic renal failure patients undergoing hemodialysis: experience of a center in Turkey. Am J Gastroenterol 2003;98:813–820.
10.
Hahn JS, Lee HL, Park JY, et al: Prevalence of gallstone disease in patients with end-stage renal disease treated with hemodialysis in Korea. Hepatogastroenterology 2003;50:1792–1795.
11.
Badalamenti S, DeFazio C, Castelnovo C, et al: High prevalence of silent gallstone disease in dialysis patients. Nephron 1994;66:225–227.
12.
Li Vecchi M, Cesare S, Soresi M, et al: Prevalence of biliary lithiasis in a Sicilian population of hemodialysis patients. Clin Nephrol 2001;55:127–132.
13.
Li Vecchi M, Soresi M, Cusimano R, et al: Prevalence of biliary lithiasis in a Sicilian population of chronic renal failure patients. Nephrol Dial Transplant 2003;18:2321–2324.
14.
Imai E, Horio M, Nitta K, et al: Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007;11:41–50.
15.
Eknoyan G: The burden of kidney disease: improving global outcomes. Kidney Int 2004;66:1310–1314.
16.
Marschall HU, Einarsson C: Gallstone disease. J Intern Med 2007;261:529–542.
17.
Mareckova O, Skala I, Marecek Z, et al: Bile composition in patients with chronic renal insufficiency. Nephrol Dial Transplant 1990;5:423–425.
18.
Barut I, Tarhan OR, Baykal B, et al: Higher incidence of cholelithiasis in chronic renal failure patients with secondary hyperparathyroidism undergoing peritoneal dialysis. Ren Fail 2007;29:453–457.
19.
Akdag I, Yilmaz Y, Kahvecioglu S, et al: Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Nephron Clin Pract 2008;108:c99–c105.
20.
De Santis A, Attili AF, Ginanni Corradini S, et al: Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 1997;25:787–790.
21.
Schafmayer C, Hartleb J, Tepel J, et al: Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany. BMC Gastroenterol 2006;6:36.
22.
Liu CM, Tung TH, Chou P, et al: Clinical correlation of gallstone disease in a Chinese population in Taiwan: experience at Cheng Hsin General Hospital. World J Gastroenterol 2006;12:1281–1286.
23.
Gelber RP, Kurth T, Kausz AT, et al: Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005;46:871–880.
24.
Tsunoda K, Shirai Y, Hatakeyama K: Prevalence of cholesterol gallstones positively correlates with per capita daily calorie intake. Hepatogastroenterology 2004;51:1271–1274.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.